1. Scrip
  3. >>Clinical Trials

Neurocrine Shines In Congenital Adrenal Hyperplasia, But Competitor Is Close

 
• By Emily Hayes

Spruce's competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.

golden gift boxes isolated on white background

Neurocrine Biosciences Inc.'s Phase II data for its NBI-74788 – a corticotropin-releasing factor type 1 (CRF1) receptor antagonist – in adults with classic congenital adrenal hyperplasia (CAH) managed to beat that of competing start-up Spruce Biosciences to the punch.

The orphan disease is associated with lack of the stress hormone cortisol and overproduction of androgens. Overproduction of androgens can cause excess growth of body hair and enlarged genitalia in females and testicular tumors in males

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from R&D